Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991:67 Suppl 5:S54-6.

Open comparative study to assess the efficacy and safety of two calcium antagonists, amlodipine and diltiazem, in the treatment of symptomatic myocardial ischaemia

Affiliations
  • PMID: 1839442
Clinical Trial

Open comparative study to assess the efficacy and safety of two calcium antagonists, amlodipine and diltiazem, in the treatment of symptomatic myocardial ischaemia

S Caponnetto et al. Postgrad Med J. 1991.

Abstract

Patients with symptomatic myocardial ischaemia received amlodipine (once daily) or diltiazem (three times daily) for 10 weeks. Amlodipine and diltiazem showed comparable efficacy in reducing angina attack rates and glyceryl trinitrate consumption. Amlodipine produced a significantly greater reduction in the mean rate pressure product. Both drugs were well tolerated with only mild side effects occurring at the higher doses. In two cases, side effects were also reported at the lower dose of diltiazem (30 mg three times daily); none occurred with the 5-mg daily dose of amlodipine. In the overall clinical assessment, efficacy of amlodipine was considered excellent in 100% of cases as compared with 40% for diltiazem. Amlodipine is clearly effective when administered once daily for the treatment of myocardial ischaemia.

PubMed Disclaimer

LinkOut - more resources